Peps
What is Octreotide?
Octreotide is a somatostatin-related medicine used in specialist endocrine and gastrointestinal care. Immediate- and long-acting preparations have different roles.
Biological role or research focus
Somatostatin-related hormone control.
Its use for specific hormone-secreting conditions does not imply a general wellness benefit.
Role reference: MedlinePlus · Octreotide ↗
Names you may encounter
Sandostatin
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Somatostatin analogue
- Main research area
- Hormone-related symptoms and selected tumors
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Octreotide ↗
Molecular structure
Mechanism & research rationale
It suppresses release of selected hormones and secretory signals. Clinical research separately measures hormone-related symptoms and tumor progression.
Source: MedlinePlus · Octreotide ↗
Medicine status & clinical context
Octreotide medicines are used in specified acromegaly, carcinoid-tumor symptom, and VIPoma settings. Immediate-release and long-acting products have different clinical roles; a study of one preparation does not establish equivalence of every octreotide product.
The medication reference describes acromegaly and symptoms associated with carcinoid tumors or VIP-secreting tumors. PROMID adds evidence about growth control in a specific midgut neuroendocrine-tumor population.
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2009
PROMID
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
- Population / model
- 85 patients with metastatic, well-differentiated midgut neuroendocrine tumors.
- Study design
- Long-acting octreotide versus placebo; planned interim analysis.
- Main finding
- Median time to tumor progression was 14.3 versus 6 months, with a hazard ratio of 0.34.
- Limits & context
- Too few deaths had occurred for a confirmatory survival conclusion. Tumor-growth control and relief of hormone-related symptoms are distinct outcomes; tumor subtype remains central.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Octreotide. ↗
Neonatal network : NN · 2006 Sep-Oct · Journal Article, Review
Use of octreotide for the treatment of protein-losing enteropathy in dogs: Retrospective study of 18 cases. ↗
Journal of veterinary internal medicine · 2024 Jan-Feb · Multicenter Study, Journal Article
Read available full text ↗
Octreotide in hyperinsulinism. ↗
The Annals of pharmacotherapy · 1997 Feb · Journal Article, Review
Octreotide and Octreotide-derived delivery systems. ↗
Journal of drug targeting · 2023 Jul · Journal Article, Review
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Key precautions
Gallbladder issues, glucose changes, digestive symptoms, and cardiac or thyroid considerations may require monitoring. The formulation and coexisting conditions affect the precautions.
Source: MedlinePlus · Octreotide ↗
Official product context · checked October 4, 2026
Blood-glucose changes, gallbladder symptoms, heart-rate changes, and thyroid-related effects appear in the medication information. A trial response should be considered alongside these product-specific precautions.
Source: MedlinePlus · Octreotide injection ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- Its use for specific hormone-secreting conditions does not imply a general wellness benefit.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does longer time to progression mean longer survival was proven?
No. PROMID’s initial survival analysis was not confirmatory.
Source: MedlinePlus · Octreotide ↗
Does every formulation have the same instructions?
No. Immediate-release and long-acting products differ, and one product’s regimen cannot be inferred from another.
Does the official medicine reference cover every use discussed online?
No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.
References & editorial record
- MedlinePlus · Octreotide ↗
- Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.